

Jan TrÅ, st JÅ, rgensen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/600591/publications.pdf>

Version: 2024-02-01

56
papers

1,369
citations

361045

20
h-index

344852

36
g-index

57
all docs

57
docs citations

57
times ranked

1678
citing authors

#	ARTICLE	IF	CITATIONS
1	Companion Diagnostics and Predictive Biomarkers for MET-Targeted Therapy in NSCLC. <i>Cancers</i> , 2022, 14, 2150.	1.7	14
2	Missing Companion Diagnostic for US Food and Drug Administrationâ€‘Approved Hematological and Oncological Drugs. <i>JCO Precision Oncology</i> , 2022, , .	1.5	1
3	Companion and complementary diagnostics: A key to precision medicine. , 2021, , 97-107.		0
4	MET deletion is a frequent event in gastric/gastroesophageal junction/esophageal cancer: a cross-sectional analysis of gene status and signal distribution in 1,580 patients. <i>Annals of Translational Medicine</i> , 2021, 9, 225-225.	0.7	2
5	Predictive biomarkers and clinical evidence. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2021, 128, 642-648.	1.2	9
6	An update on companion and complementary diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 445-454.	1.5	4
7	The current landscape of the FDA approved companion diagnostics. <i>Translational Oncology</i> , 2021, 14, 101063.	1.7	32
8	A Companion Diagnostic With Significant Clinical Impact in Treatment of Breast and Gastric Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 676939.	1.3	20
9	Oncology drug-companion diagnostic combinations. <i>Cancer Treatment and Research Communications</i> , 2021, 29, 100492.	0.7	13
10	Site-agnostic biomarker-guided oncology drug development. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 583-592.	1.5	10
11	Companion and complementary diagnostics: an important treatment decision tool in precision medicine. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 557-559.	1.5	8
12	PD-L1 expression and efficacy of pembrolizumab as monotherapy in NSCLC. <i>Chinese Clinical Oncology</i> , 2020, 9, 60-60.	0.4	5
13	An Introduction to Companion and Complementary Diagnostics. , 2019, , 1-10.		1
14	The Drug-Diagnostic Codevelopment Model. , 2019, , 11-25.		0
15	Regulatory Requirements for Companion Diagnostics and Drugâ€‘Diagnostic Codevelopment in the United States. , 2019, , 307-318.		1
16	Twenty Years with Personalized Medicine: Past, Present, and Future of Individualized Pharmacotherapy. <i>Oncologist</i> , 2019, 24, e432-e440.	1.9	36
17	A paradigm shift in biomarker guided oncology drug development. <i>Annals of Translational Medicine</i> , 2019, 7, 148-148.	0.7	25
18	The Development of the HercepTestâ„¢ â€‘ from Bench to Bedside. , 2019, , 43-60.		5

#	ARTICLE	IF	CITATIONS
19	Developing Molecular Diagnostics in Cancer. , 2019, , 1-20.		0
20	Pharmacodiagnosics and Personalized Medicine in Cancer. , 2019, , 325-344.		0
21	When biomarkers define a drug indication. Expert Review of Molecular Diagnostics, 2018, 18, 315-317.	1.5	7
22	The ESMO Precision Medicine Glossary. Annals of Oncology, 2018, 29, 781-782.	0.6	1
23	Clinical and Regulatory Aspects of Companion Diagnostic Development in Oncology. Clinical Pharmacology and Therapeutics, 2018, 103, 999-1008.	2.3	31
24	Companion and complementary diagnostics for first-line immune checkpoint inhibitor treatment in non-small cell lung cancer. Translational Lung Cancer Research, 2018, 7, S95-S99.	1.3	7
25	Companion Diagnostics: From Biomarkers to Diagnostics. , 2017, , 530-545.		2
26	Gene Signal Distribution and <i>HER2</i> Amplification in Gastroesophageal Cancer. Journal of Cancer, 2017, 8, 1517-1524.	1.2	8
27	Detection of MET amplification in gastroesophageal tumor specimens using IQFISH. Annals of Translational Medicine, 2017, 5, 458-458.	0.7	5
28	<i>HER2</i> amplification and gene signal distribution in gastroesophageal cancer.. Journal of Clinical Oncology, 2017, 35, e15600-e15600.	0.8	0
29	Companion diagnostics—a tool to improve pharmacotherapy. Annals of Translational Medicine, 2016, 4, 482-482.	0.7	57
30	Companion and Complementary Diagnostics: Clinical and Regulatory Perspectives. Trends in Cancer, 2016, 2, 706-712.	3.8	49
31	Assessment of HER2 amplification status in breast cancer using a new automated HER2 IQFISH pharmDx, (Dako Omnis) assay. Pathology Research and Practice, 2016, 212, 735-742.	1.0	11
32	The importance of predictive biomarkers in oncology drug development. Expert Review of Molecular Diagnostics, 2016, 16, 807-809.	1.5	14
33	Companion diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC. Expert Review of Molecular Diagnostics, 2016, 16, 131-133.	1.5	52
34	Analysis of HER2 status in gastroesophageal tumor specimens using a new automated HER2 IQFISH pharmDx, (Dako Omnis) assay. Histology and Histopathology, 2016, 31, 1327-35.	0.5	5
35	Companion diagnostics: the key to personalized medicine. Expert Review of Molecular Diagnostics, 2015, 15, 153-156.	1.5	41
36	Clinical application of companion diagnostics. Trends in Molecular Medicine, 2015, 21, 405-407.	3.5	31

#	ARTICLE	IF	CITATIONS
37	Companion Diagnostics for Targeted Cancer Drugs – Clinical and Regulatory Aspects. <i>Frontiers in Oncology</i> , 2014, 4, 105.	1.3	77
38	Drug-Diagnostics Co-Development in Oncology. <i>Frontiers in Oncology</i> , 2014, 4, 208.	1.3	4
39	Role of human epidermal growth factor receptor 2 in gastric cancer: Biological and pharmacological aspects. <i>World Journal of Gastroenterology</i> , 2014, 20, 4526.	1.4	40
40	Companion Diagnostics in Oncology - Current Status and Future Aspects. <i>Oncology</i> , 2013, 85, 59-68.	0.9	32
41	A new manganese-based oral contrast agent (CMC-001) for liver MRI: pharmacological and pharmaceutical aspects. <i>Acta Radiologica</i> , 2012, 53, 707-713.	0.5	6
42	HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature. <i>Journal of Cancer</i> , 2012, 3, 137-144.	1.2	219
43	Companion Diagnostics and the Drug-Diagnostic Codevelopment Model. <i>Drug Development Research</i> , 2012, 73, 390-397.	1.4	10
44	A challenging drug development process in the era of personalized medicine. <i>Drug Discovery Today</i> , 2011, 16, 891-897.	3.2	44
45	High Concordance Between Two Companion Diagnostics Tests. <i>American Journal of Clinical Pathology</i> , 2011, 136, 145-151.	0.4	19
46	Targeted HER2 Treatment in Advanced Gastric Cancer. <i>Oncology</i> , 2010, 78, 26-33.	0.9	132
47	Drug-Diagnostic Co-Development in Cancer. <i>Pharmaceutical Medicine</i> , 2010, 24, 363-375.	1.0	10
48	New Era of Personalized Medicine: A 10-Year Anniversary. <i>Oncologist</i> , 2009, 14, 557-558.	1.9	30
49	The new era of personalized medicine: 10 years later. <i>Personalized Medicine</i> , 2009, 6, 423-428.	0.8	7
50	The value of <i>TOP2A</i> gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D. <i>Acta Oncologica</i> , 2008, 47, 725-734.	0.8	101
51	Prognostic significance of numeric aberrations of genes for thymidylate synthase, thymidine phosphorylase and dihydrofolate reductase in colorectal cancer. <i>Acta Oncologica</i> , 2008, 47, 1054-1061.	0.8	21
52	Are we approaching the post-blockbuster era? Pharmacodiagnosics and rational drug development. <i>Expert Review of Molecular Diagnostics</i> , 2008, 8, 689-695.	1.5	24
53	From blockbuster medicine to personalized medicine. <i>Personalized Medicine</i> , 2008, 5, 55-63.	0.8	19
54	Pharmacodiagnosics and Targeted Therapies – A Rational Approach for Individualizing Medical Anticancer Therapy in Breast Cancer. <i>Oncologist</i> , 2007, 12, 397-405.	1.9	37

#	ARTICLE	IF	CITATIONS
55	Improvement of Patient Convenience in Treatment with Growth Hormone. Journal of Pediatric Endocrinology and Metabolism, 1994, 7, 175-80.	0.4	20
56	Development, production and pharmacodynamics of human growth hormone. Indian Journal of Pediatrics, 1991, 58, 23-32.	0.3	2